Literature DB >> 1277266

The migration of lymphocytes across specialized vascular endothelium. II. The contrasting consequences of treating lymphocytes with tryspin or neuraminidase.

W L Ford, M Sedgley, S M Sparshott, M E Smith.   

Abstract

Lymphocytes were exposed in vitro to either trypsin or neuraminidase. The ability of the treated cells to migrate into tissues were measured (a) by i.v. injection into intact recipients and (b) by vascular perfusion through an isolated lymph-node preparation. The localization of trypsinized cells in the lymph-nodes of recipients was deficient when compared to untreated lymphocytes and there was a surplus of trypsinized cells in blood. Trypsinized cells migrated into the isolated nodes in reduced numbers. By contrast, neuraminidase treated lymphocytes were markedly deficient in the blood of recipients early after injection; their localization in the spleen and lymph-nodes was also deficient but they were in surplus in the liver. Moreover they migrated into the isolated nodes in slightly increased numbers. By 24 hr after injection the perturbed localization pattern produced by either enzyme was partly restored to normal. In conclusion, tryspin interfered with the capacity of lymphocytes to migrate into lymph-nodes but neuraminidase did not; the latter promoted the hepatic sequestration of cells and the reduced localization in the blood and tissues was a consequence of this. The hypothesis that lymphocytes adhere to specialized endothelia in lymph-nodes because of specific glycoside sequences on their surface lacks experimental support.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1277266

Source DB:  PubMed          Journal:  Cell Tissue Kinet        ISSN: 0008-8730


  10 in total

Review 1.  Microvascular endothelial cell heterogeneity: interactions with leukocytes and tumor cells.

Authors:  P N Belloni; R J Tressler
Journal:  Cancer Metastasis Rev       Date:  1990-02       Impact factor: 9.264

2.  Mechanisms of lymphocyte adhesion to human vascular endothelial cells in culture. T lymphocyte adhesion to endothelial cells through endothelial HLA-DR antigens induced by gamma interferon.

Authors:  J Masuyama; N Minato; S Kano
Journal:  J Clin Invest       Date:  1986-05       Impact factor: 14.808

3.  Origin and immunological hyporeactivity of canine alveolar lymphocytes.

Authors:  J Kirby; A Wood; J Reader; K Isted; J Hynd; D Hawkes; L Hudson; J Pepper
Journal:  Immunology       Date:  1985-07       Impact factor: 7.397

4.  The effect of vitamin A depletion on antigen-stimulated trapping of peripheral lymphocytes in local lymph nodes of rats.

Authors:  H Takagi; K Nakano
Journal:  Immunology       Date:  1983-01       Impact factor: 7.397

5.  Cyclic AMP reduces and cyclic GMP increases the traffic of lymphocytes through peripheral lymph nodes of sheep in vivo.

Authors:  T C Moore; P J Lachmann
Journal:  Immunology       Date:  1982-11       Impact factor: 7.397

6.  Lymphocyte cell surface glycoproteins which bind to soybean and peanut lectins.

Authors:  W R Brown; A F Williams
Journal:  Immunology       Date:  1982-08       Impact factor: 7.397

7.  Migration of human lymphocytes. II. Variation of lymphocyte distribution.

Authors:  K Morgan; P J Holt
Journal:  Immunology       Date:  1978-12       Impact factor: 7.397

8.  Germinal center B cells lack homing receptors necessary for normal lymphocyte recirculation.

Authors:  R A Reichert; W M Gallatin; I L Weissman; E C Butcher
Journal:  J Exp Med       Date:  1983-03-01       Impact factor: 14.307

9.  The role of serine proteases and serine protease inhibitors in the migration of gonadotropin-releasing hormone neurons.

Authors:  Paola T Drapkin; Denis Monard; Ann-Judith Silverman
Journal:  BMC Dev Biol       Date:  2002-02-05       Impact factor: 1.978

10.  Protein kinase C-dependent effects of 12(S)-HETE on endothelial cell vitronectin receptor and fibronectin receptor.

Authors:  D G Tang; Y Q Chen; C A Diglio; K V Honn
Journal:  J Cell Biol       Date:  1993-05       Impact factor: 10.539

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.